China
In the final part of a series on challenging patent invalidation decisions in China, lawyers at Spruson & Ferguson and Marshall Gerstein share how courts adjudicate appeals
Newly independent King & Wood has established offices in North America, while Mallesons has entered a ‘new era’ with a 1,200-lawyer firm across Australia and Singapore
In the first of a two-part article, lawyers at Spruson & Ferguson and Marshall Gerstein provide an overview of China’s system for appealing against patent invalidation decisions
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyXiaoping Wu and Jicheng Yang of Wanhuida Intellectual Property analyse an invalidation decision that addresses how dosage and administration features affect the inventiveness assessment of pharmaceutical use claims in China -
Sponsored by CCPIT Patent and Trademark Law OfficeThe revised Patent Examination Guidelines foster innovation by redefining plant varieties, says Juhua Luo of CCPIT Patent and Trademark Law Office
-
Sponsored by CCPIT Patent and Trademark Law OfficeNew CNIPA examination practices on non-use cancellation raise evidentiary requirements for petitioners. Ling Zhao of CCPIT Patent and Trademark Law Office highlights the implications for registrants and enforcement strategies in China
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property explains how the CNIPA’s rulings on mirogabalin besylate tablets highlight the importance of formulation patent drafting and claim amendments in China’s drug patent landscape
-
Sponsored by CCPIT Patent and Trademark Law OfficeHongxia Wu of CCPIT Patent and Trademark Law Office outlines the potential impact of the 2025 amendments on overseas companies operating in the country
-
Sponsored by Wanhuida Intellectual PropertyXiaoping Wu of Wanhuida Intellectual Property explains how the CNIPA’s recent invalidation of a sustained-release patent illustrates key considerations in assessing inventive step for pharmaceutical formulation patents
